Verition Fund Management
CORT icon

Verition Fund Management’s Corcept Therapeutics CORT Stock Holding History

Verition Fund Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-91,034
Closed -$3.17M – 2520
2025
Q4 		$3.17M Buy
91,034
+88,412
+3,372% +$6.94M 0.01% 1203
2025
Q3 		$218K Buy
+2,622
New +$190K ﹤0.01% 3449
2025
Q2 		– Sell
-10,122
Closed -$1.16M – 3664
2025
Q1 		$1.16M Buy
+10,122
New +$616K 0.01% 2019
2024
Q4 		– Sell
-8,758
Closed -$405K – 3280
2024
Q3 		$405K Sell
8,758
-28,931
-77% -$1.03M ﹤0.01% 2453
2024
Q2 		$1.22M Buy
+37,689
New +$1.03M 0.01% 1552
2023
Q3 		– Sell
-10,944
Closed -$244K – 2395
2023
Q2 		$244K Buy
+10,944
New +$252K ﹤0.01% 1713

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Verition Fund Management's CORT Position: Q1 2026 in Review

Verition Fund Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 91,034 shares — an estimated $3.17M sold.

Verition Fund Management first reported a position in CORT in Q2 2023 and held it in 6 quarters. The position peaked at $3.17M in Q4 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Verition Fund Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 91,034 Corcept Therapeutics shares in Q1 2026, an estimated $3.17M.
  • Verition Fund Management first reported a position in Corcept Therapeutics in Q2 2023 and held it in 6 quarters.
  • Verition Fund Management's Corcept Therapeutics position peaked at $3.17M in Q4 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.